| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6656935 | METUCHEN PHARMS | Aromatic nitrogen-containing 6-membered cyclic compounds |
Apr, 2025
(11 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7501409 | METUCHEN PHARMS | Preparations for oral administration |
May, 2023
(11 months ago) | |
Stendra is owned by Metuchen Pharms.
Stendra contains Avanafil.
Stendra has a total of 2 drug patents out of which 1 drug patent has expired.
Expired drug patents of Stendra are:
- US7501409
Stendra was authorised for market use on 27 April, 2012.
Stendra is available in tablet;oral dosage forms.
Stendra can be used as treatment of erectile dysfunction.
Drug patent challenges can be filed against Stendra from 27 April, 2016.
The generics of Stendra are possible to be released after 18 October, 2025.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-282) | Oct 18, 2025 |
| New Dosing Schedule(D-140) | Sep 17, 2017 |
| New Chemical Entity Exclusivity(NCE) | Apr 27, 2017 |
Drugs and Companies using AVANAFIL ingredient
NCE-1 date: 27 April, 2016
Market Authorisation Date: 27 April, 2012
Treatment: Treatment of erectile dysfunction
Dosage: TABLET;ORAL
How can I launch a generic of STENDRA before it's drug patent expiration?
More Information on Dosage
STENDRA family patents
